6:28 PM
 | 
Sep 17, 2012
 |  BC Extra  |  Company News

FDA says delafloxacin qualifies for incentives under GAIN

FDA granted the first publically announced Qualified Infectious Disease Product (QIDP) designation to delafloxacin from Rib-X Pharmaceuticals Inc. (New Haven, Conn.) to treat acute bacterial skin and skin...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >